Explore the latest pharmaceutical research, new drug developments, and FDA approvals. Stay informed on the therapies transforming disease management, from cancer treatments to chronic disease medications.
Inflammatory disease biotech pursues unprecedented combination of drug development and Ethereum treasury management In an unusual move for biotechnology, 180 Life Sciences announced a massive
Inflammatory disease biotech pursues unprecedented combination of drug development and Ethereum treasury management In an unusual move for biotechnology, 180 Life Sciences announced a massive
The FDA has imposed significant restrictions on Bluebird Bio’s Skysona gene therapy following the emergence of concerning cancer risks in treated patients. This regulatory action
The FDA has granted approval to Hernexeos, a breakthrough targeted therapy for advanced lung cancer, marking a significant milestone in oncology treatment options for patients
The FDA has unveiled its ambitious PreCheck program, a strategic initiative designed to fast-track the regulatory review of pharmaceutical manufacturing facilities and strengthen America’s domestic
Eli Lilly’s highly anticipated oral obesity treatment orforglipron delivered solid but underwhelming results in its Phase 3 trial, triggering a dramatic market reaction that wiped
Strategic Pipeline Focus as Competitive Pressures Mount Against Lilly Novo Nordisk’s recent decision to drop two obesity drug candidates—another GLP-1/GIP co-agonist and CB1 receptor as
In a significant leap forward for medtech innovation, ARS Pharmaceuticals has secured FDA approval for Neffy 1 mg, the first needle-free epinephrine nasal spray designed
Key Takeaways: FDA approvals in 2025 have highlighted therapies addressing rare diseases, oncology, and chronic conditions. Innovative drugs with new mechanisms of action are transforming
Overview: A look at the major biotech, medtech, and pharma conferences in 2025. Key Details: Dates, locations, and highlights from each event. Industry Impact: Why
